Effect of muscle selection for botulinum neurotoxin treatment on spasticity in patients with post-stroke elbow flexor muscle over-activity: an observational prospective study

References

• Andringa A, van de Port I, van Wegen E, Ket J, Meskers C, Kwakkel G. 2019. Effectiveness of botulinum toxin treatment for upper limb spasticity poststroke over different ICF domains: a systematic review and meta-Analysis. Arch Phys Med Rehabil. 100(9):1703–1725.
   PubMed Web of Science ®Google Scholar
• Armstrong AD, MacDermid JC, Chinchalkar S, Stevens RS, King GJ. 1998. Reliability of range-of-motion measurement in the elbow and forearm. J Shoulder Elbow Surg. 7(6):573–580.
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, et al. 2000. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 31(10):2402–2406.
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L. 2001. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 8(6):559–565.
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Zakine B, Maisonobe P, Aymard C, Fhedoroff K, Hefter H, Jacinto J, Jost WH, Molteni F, Stam H, et al. 2010. The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. Int J Rehabil Res. 33(3):199–204.
   PubMed Web of Science ®Google Scholar
• Basmajian JV, Latif A. 1957. Integrated actions and functions of the chief flexors of the elbow: a detailed electromyographic analysis. J Bone Joint Surg Am. 39-A(5):1106–1118.
   PubMed Web of Science ®Google Scholar
• Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. 2000. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 69(2):217–221.
   PubMed Web of Science ®Google Scholar
• Bohannon RW, Smith MB. 1987. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 67(2):206–207.
   PubMed Web of Science ®Google Scholar
• Boland MR, Spigelman T, Uhl TL. 2008. The function of brachioradialis. J Hand Surg Am. 33(10):1853–1859.
   PubMedGoogle Scholar
• Boyd RN, Graham HK. 1999. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 6(suppl 4):S23–S35.
   PubMed Web of Science ®Google Scholar
• Brunnstrom S. 1966. Motor testing procedures in hemiplegia: based on sequential recovery stages. Phys Ther. 46(4):357–375.
   PubMedGoogle Scholar
• Clinical Review Report 2017. AbobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada, Inc.): Indication: For the symptomatic treatment of focal spasticity affecting the upper limbs in adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health.
   Google Scholar
• Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, Walcott JM, Jenkins SW, Turkel C, Molloy PT. 2004. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 85(7):1063–1069.
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S, PROS Study Group 2012. Patient registry of outcomes in spasticity care. Am J Phys Med Rehabil. 91(9):729–746.
   PubMed Web of Science ®Google Scholar
• Funk DA, An KN, Morrey BF, Daube JR. 1987. Electromyographic analysis of muscles across the elbow joint. J Orthop Res. 5(4):529–538.
   PubMed Web of Science ®Google Scholar
• Genet F, Schnitzler A, Droz-Bartholet F, Salga M, Tatu L, Debaud C, Denormandie P, Parratte B. 2017. Successive motor nerve blocks to identify the muscles causing a spasticity pattern: example of the arm flexion pattern. J Anat. 230(1):106–116.
   PubMed Web of Science ®Google Scholar
• Gracies JM. 2005. Pathophysiology of spastic paresis. II: emergence of muscle overactivity. Muscle Nerve. 31(5):552–571.
   PubMed Web of Science ®Google Scholar
• Gracies JM, Burke K, Clegg NJ, Browne R, Rushing C, Fehlings D, Matthews D, Tilton A, Delgado MR. 2010. Reliability of the Tardieu Scale for assessing spasticity in children with cerebral palsy. Arch Phys Med Rehabil. 91(3):421–428.
   PubMed Web of Science ®Google Scholar
• Hefter H, Jost WH, Reissig A, Zakine B, Bakheit AM, Wissel J. 2012. Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment? Int J Rehabil Res. 35(3):227–233.
   PubMed Web of Science ®Google Scholar
• Keenan MA, Haider TT, Stone LR. 1990. Dynamic electromyography to assess elbow spasticity. J Hand Surg Am. 15(4):607–614.
   PubMedGoogle Scholar
• Kleiber T, Kunz L, Disselhorst-Klug C. 2015. Muscular coordination of biceps brachii and brachioradialis in elbow flexion with respect to hand position. Front Physiol. 6:215.
   PubMed Web of Science ®Google Scholar
• Li F, Wu Y, Li X. 2014. Test-retest reliability and inter-rater reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in hemiplegic patients with stroke. Eur J Phys Rehabil Med. 50(1):9–15.
   PubMed Web of Science ®Google Scholar
• Lim YH, Choi EH, Lim JY. 2016. Comparison of effects of botulinum toxin injection between subacute and chronic stroke patients: a pilot study. Medicine (Baltimore). 95(7):e2851.
   PubMed Web of Science ®Google Scholar
• McCrory P, Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Sandanam J, Davies L, Munns M, Hughes A. 2009. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med. 41(7):536–544.
   PubMed Web of Science ®Google Scholar
• Mehrholz J, Wagner K, Meißner D, Grundmann K, Zange C, Koch R, Pohl M. 2005. Reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in adult patients with severe brain injury: a comparison study. Clin Rehabil. 19(7):751–759.
   PubMed Web of Science ®Google Scholar
• Rosales RL, Bigalke H, Dressler D. 2006. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 13(Suppl 1):2–10.
   PubMed Web of Science ®Google Scholar
• Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L, Investigators B. 2010. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess. 14(26):1–113.
   PubMed Web of Science ®Google Scholar
• Shaw LC, Price CI, van Wijck FM, Shackley P, Steen N, Barnes MP, Ford GA, Graham LA, Rodgers H, BoTULS Investigators 2011. Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: effect on impairment, activity limitation, and pain. Stroke. 42(5):1371–1379.
   PubMed Web of Science ®Google Scholar
• Simpson LL. 1981. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 33(3):155–188.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP. 1996. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 46(5):1306–1310.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Esquenazi A, Graham GD, McGuire JR, Odderson I. 2017. OnabotulinumtoxinA injection for poststroke upper-limb spasticity: guidance for early injectors from a delphi panel process. Pm R. 9(2):136–148.
   PubMedGoogle Scholar
• Sloop RR, Escutin RO, Matus JA, Cole BA, Peterson GW. 1996. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology. 46(5):1382–1386.
   PubMed Web of Science ®Google Scholar
• Suputtitada A, Suwanwela NC. 2005. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil. 27(4):176–184.
   PubMed Web of Science ®Google Scholar
• Şengül İ, Aşkin A, Bayram K, Tosun A. 2018. Assessment of post-stroke elbow flexor spasticity in different forearm positions. Somatosens Mot Res. 35(3-4):218–222.
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P. 2013. Results from the Upper Limb International Spasticity Study-II (ULISII): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open. 3(6):e002771.
   PubMed Web of Science ®Google Scholar
• Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, Deruyter F, Eng JJ, Fisher B, Harvey RL, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research, et al. 2016. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 47(6):e98–e169.
   PubMed Web of Science ®Google Scholar